|1.||Pfeifer, Andrea: 6 articles (01/2014 - 01/2012)|
|2.||Muhs, Andreas: 6 articles (01/2014 - 01/2012)|
|3.||Froestl, Wolfgang: 6 articles (01/2014 - 01/2012)|
|4.||Hemmelgarn, Brenda: 3 articles (11/2013 - 01/2012)|
|5.||Straus, Sharon E: 3 articles (11/2013 - 01/2012)|
|6.||Chen, Maggie H: 3 articles (11/2013 - 01/2012)|
|7.||Tricco, Andrea C: 3 articles (11/2013 - 01/2012)|
|8.||Soobiah, Charlene: 3 articles (11/2013 - 01/2012)|
|9.||Weiner, Ina: 3 articles (08/2011 - 03/2009)|
|10.||Borrie, Michael: 2 articles (01/2015 - 02/2009)|
01/01/2001 - "For patients with mild dementia (baseline MMSE score between 21 and 26), there was a significantly greater deterioration on the MMSE scale for each time-point in the nootropics group compared with the AChE-Is group. "
01/01/2001 - "In patients with moderate dementia (baseline MMSE between 11 and 20), however, there was a significantly greater deterioration, as shown on the CAMCOG scale, after 12 months' treatment for patients receiving AChE-Is compared with those receiving nootropics (-4.38 for AChE-Is group versus 1.48 for nootropics group). "
08/01/2012 - "Cohort data indicate that use of nootropics and Ginkgo biloba extract may be associated with a reduced incidence of dementia and death. "
05/01/1992 - "Proof of efficacy of nootropics for the indication "dementia" (phase III)--recommendations."
05/01/2014 - "This study compared utilization of selected cognitive enhancers among elderly patients with dementia and estimated associated differences in medical care costs. "
|2.||Alzheimer Disease (Alzheimer's Disease)
05/01/1997 - "Recent data suggest that long term administration of nootropics may lead to a significant improvement of cognitive functions in Alzheimer's disease patients compared with untreated individuals, having excellent tolerability. "
09/01/2007 - "To review the literature for double-blind, placebo-controlled trials that examined the efficacy of cognitive enhancers in the psychopathology of Alzheimer's disease. "
01/01/2012 - "Efficacy of cognitive enhancers for Alzheimer's disease: protocol for a systematic review and network meta-analysis."
01/01/2015 - "Few treatments exist for gait impairment in Alzheimer's disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. "
06/01/2007 - "Despite numerous clinical trials, it is unknown whether ethnicity affects treatment response to cognitive enhancers in Alzheimer's disease (AD). "
|3.||Memory Disorders (Memory Loss)
01/01/2015 - "Here we critically review advances in research of these emerging molecular targets for the treatment of memory disorders, and discuss their advantages over currently used cognitive enhancers as well remaining challenges. "
12/31/1993 - "Knowledge of the neurobiological mechanisms by which the cholinergic system can attenuate age-related memory loss can facilitate the development of effective cognitive enhancers. "
01/01/1992 - "Four so-called cognitive enhancers, all widely used for the treatment of the symptoms associated with mental aging, cerebral insufficiency and senile memory disorder, were investigated in this paradigm. "
02/01/2015 - "Computational docking of a series of IRAP-specific cognitive enhancers into the crystal structure provides a molecular basis for their structure-activity relationships and demonstrates that the structure will be a powerful tool in the development of new classes of cognitive enhancers for treating a variety of memory disorders such as Alzheimer's disease. "
02/01/2014 - "Such inverse agonists, initially developed as cognitive enhancers for treatment of memory impairments, proved to be very efficient in reversing learning and memory deficits in a Down syndrome mouse model after acute treatment. "
01/01/1990 - "In an attempt to characterize the anticonvulsant efficacy of nootropics, their effect on different types of kindled seizures in rats has been studied. "
01/01/2013 - "There was a lack of seizure aggravation typical of many nootropic drugs. "
03/24/2000 - "Spontaneous EL mouse seizures were also inhibited by these nootropics with a similar rank order of potencies. "
09/01/1995 - "The nootropic drugs had little if any effect on severity of seizures. "
09/01/1987 - "To elucidate the action of substances characterized by their ability to improve learning and memory and to have an activatory, protective and function restoring effect on nerve cells in distress, the effects of nootropic drugs and of antioxidative acting substances on the development of kindling and the seizure behavior in the kindled state were investigated. "
|5.||Schizophrenia (Dementia Praecox)
02/01/2008 - "Prepulse inhibition (PPI) deficits--sensory information-processing deficits observed in schizophrenia--may be useful models for studying the efficacy of AChE inhibitors as cognitive enhancers. "
01/01/2013 - "The MATRICS Consensus Cognitive Battery (MCCB) was developed to provide a reliable, valid, and standard battery for clinical trials on cognitive enhancers in schizophrenia. "
01/01/2015 - "However, the limited data available do not allow to draw firm conclusions on the value of PDE-Is as cognitive enhancers in schizophrenia yet. "
01/01/2014 - "Specifically, motivation deficits, a type of negative symptoms, have been attracting interest as (1) a moderator of cognitive performance in schizophrenia and related disorders, and (2) a modulating factor of cognitive enhancers/remediation. "
08/01/2011 - "Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target."
|2.||Ethanol (Ethyl Alcohol)
|5.||Cholinesterase Inhibitors (Anticholinesterases)
|10.||Acetylcholine (Acetylcholine Chloride)
|1.||Activities of Daily Living (ADL)
|3.||Drug Therapy (Chemotherapy)
|4.||Deep Brain Stimulation